TG Therapeutics, Inc. $TGTX Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. boosted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 1,278.8% in the 4th quarter, HoldingsChannel reports. The fund owned 160,390 shares of the biopharmaceutical company’s stock after acquiring an additional 148,757 shares during the quarter. Assenagon Asset Management S.A.’s holdings in TG Therapeutics were worth $4,781,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Johnson Financial Group Inc. purchased a new stake in shares of TG Therapeutics during the 2nd quarter worth $25,000. Danske Bank A S purchased a new position in shares of TG Therapeutics in the 3rd quarter valued at about $25,000. Optiver Holding B.V. increased its holdings in shares of TG Therapeutics by 3,485.7% in the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 732 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of TG Therapeutics by 117.1% in the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 486 shares during the period. Finally, Salomon & Ludwin LLC acquired a new stake in shares of TG Therapeutics in the third quarter valued at about $34,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Price Performance

Shares of NASDAQ TGTX opened at $31.75 on Friday. The stock has a market cap of $5.07 billion, a price-to-earnings ratio of 11.46 and a beta of 1.87. TG Therapeutics, Inc. has a 52 week low of $25.28 and a 52 week high of $46.48. The company’s 50-day moving average price is $29.76 and its 200 day moving average price is $31.49. The company has a current ratio of 4.10, a quick ratio of 3.29 and a debt-to-equity ratio of 0.38.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). TG Therapeutics had a return on equity of 101.12% and a net margin of 72.56%.The business had revenue of $192.57 million for the quarter, compared to analyst estimates of $192.15 million. During the same quarter in the previous year, the firm posted $0.15 EPS. The business’s revenue was up 78.0% on a year-over-year basis. As a group, research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TGTX. Wall Street Zen lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. Finally, JPMorgan Chase & Co. dropped their price objective on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.